received menquadfi 26 months apart, she didn’t receive the 2nd menquadfi after the age of sixteen both were done before the patient turned 16 with no reported adverse event; Initial information received on 27-Jan-2025 regarding an unsolicited valid non-serious case received from a Other health professional. This case involves, the child female patient who received Meningococcal A-C-Y-W135 (T Conj) Vaccine [Menquadfi] 26 months apart, she didn’t receive the 2nd menquadfi after the age of sixteen both were done before the patient turned 16 with no reported adverse event. The patient’s past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect Meningococcal A-C-Y-W135 (T Conj) Vaccine Solution for injection (unknown strength, dosage, expiry date, batch number and route) via unknown administration site for prophylactic vaccination 26 months apart, she didn’t receive the 2nd menquadfi after the age of sixteen both were done before the patient turned 16 with no reported adverse event (product administered to patient of inappropriate age) (unknown latency). Reportedly, The problem is she didn’t receive the 2nd Menquadfi after the age of sixteen. Both were done before the patient turned 16 but were 26 months apart. They want to know if the patient is still immunized or do they need the booster after age of sixteen even though the patient had the 2 Menquadfi. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder’s compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.